James R. Kasinger
2021
Compensation breakdown
Non-Equity Incentive Plan | $229,500 |
---|---|
Option Awards | $2,771,741 |
Salary | $425,000 |
Stock Awards | $1,204,920 |
Other | $11,600 |
Total | $4,642,761 |
Kasinger received $2.8M in option awards, accounting for 60% of the total pay in 2021.
Kasinger also received $229.5K in non-equity incentive plan, $425K in salary, $1.2M in stock awards and $11.6K in other compensation.
Rankings
In 2021, James R. Kasinger's compensation ranked 2,849th out of 12,412 executives tracked by ExecPay. In other words, Kasinger earned more than 77.0% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,849 | 77th |
Manufacturing | 1,131 | 79th |
Chemicals And Allied Products | 449 | 81st |
Drugs | 393 | 81st |
Biological Products, Except Diagnostic Substances | 115 | 75th |
Kasinger's colleagues
We found five more compensation records of executives who worked with James R. Kasinger at CRISPR Therapeutics AG in 2021.
2021
Samarth Kulkarni
CRISPR Therapeutics AG
Chief Executive Officer
2021
Brendan Smith
CRISPR Therapeutics AG
Chief Financial Officer
2021
Tony Ho
CRISPR Therapeutics AG
Former EVP, Research and Development
2021
Lawrence Klein
CRISPR Therapeutics AG
Chief Operating Officer
2021
Michael Tomsicek
CRISPR Therapeutics AG
Chief Financial Officer
News
April 25, 2022
April 28, 2021
April 24, 2020
April 30, 2019